Globenewswire·2026-02-06 08:30Core Viewpoint - HUTCHMED will announce its final results for the year ended December 31, 2025, on March 5, 2026, with subsequent webcasts for analysts and investors to discuss the results and conduct Q&A sessions [1][2]. Company Overview - HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [4]. - The company has successfully marketed its first three medicines in China, with the first also receiving approval in the US, Europe, and Japan [4]. Event Details - The English webcast for discussing the final results will take place on March 5, 2026, at 8:00 am EST, followed by a Chinese (Putonghua) webcast on March 6, 2026, at 8:30 am HKT [2]. - Both webcasts will be available live on the company's website, with a replay accessible shortly after the events [3].